SCHEMBL266459

SCHEMBL266459

Cc1cc(O)c2ccccc2n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.64
NCF1 P14598 2/20 0.60
L3MBTL1 Q9Y468 2/20 0.58
AURKA O14965 1/20 0.51
AURKB Q96GD4 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HTT P42858 2/20 0.50
POLB P06746 1/20 0.50
RAD52 P43351 1/20 0.50
TAAR1 Q96RJ0 1/20 0.50
CYP2C19 P33261 1/20 0.50
MYC P01106 1/20 0.48
MAX P61244 1/20 0.48
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
USP2 O75604 1/20 0.47
MAPT P10636 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30199873 1.00 CYP1A2 (0.64) CYP1A2NCF1L3MBTL1AURKAAURKB
SCHEMBL28129148 0.81 L3MBTL1 (0.60) CYP1A2NCF1L3MBTL1AURKAAURKB
SCHEMBL9326676 0.78 MYC (0.52) CYP1A2MEN1KMT2APOLBMYC
SCHEMBL89010 0.78 CYP1A2 (1.00) CYP1A2NCF1L3MBTL1KMT2APOLB
SCHEMBL64767 0.78 MYC (0.52) CYP1A2L3MBTL1MEN1KMT2AHTT
SCHEMBL29376440 0.78 MYC (0.52) CYP1A2L3MBTL1MEN1KMT2AHTT
SCHEMBL29502790 0.78 CYP1A2 (1.00) CYP1A2NCF1L3MBTL1KMT2APOLB
SCHEMBL5033387 0.78 KDM4E (0.43) CYP1A2L3MBTL1POLBKDM4EALDH1A1
SCHEMBL3760247 0.78 LMNA (0.61) CYP1A2L3MBTL1MEN1KMT2AHTT
SCHEMBL6593684 0.78 CYP1A2 (0.50) CYP1A2L3MBTL1POLBKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118791429-A Preparation method of 4-chloroquinaldine 湖北省宏源药业科技股份有限公司 2024-10-18 CN claimed
US-20240269308-A1 PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2024-08-15 US claimed
WO-2024138000-A1 PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2024-06-27 WO claimed
CN-118047720-A Preparation method of dequalinium chloride 美享生物科技(海南)有限公司 2024-05-17 CN claimed
CN-116396653-B Method for preparing metal-organic polymer coating based on latticed supermolecular monomer 五邑大学 2024-02-09 CN claimed
CN-116396653-A Method for preparing metal-organic polymer coating based on latticed supermolecular monomer 五邑大学 2023-07-07 CN claimed
CN-115286622-A Quinoline ring-containing 1,2, 4-oxadiazole substituted benzamide compound and preparation method and application thereof 浙江工业大学 2022-11-04 CN claimed
CN-114034693-A Combined test paper for detecting urine creatinine urine microalbumin semiquantitative, preparation method and application thereof 广州达安基因股份有限公司 2022-02-11 CN claimed
US-20220015363-A1 SMALL MOLECULE PATHOGEN DISPERSAL AGENT THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2022-01-20 US claimed
CN-111704633-A Mo catalyst and application thereof in preparation of 9, 10-epoxy-1, 5-cyclododecadiene 万华化学集团股份有限公司 2020-09-25 CN claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 WO claimed
US-RE35601-E Delivery device providing beneficial agent stability ALZA CORPORATION (US) 1997-09-02 US claimed
US-5373015-A Treating hypertension and congestive heart failure IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1994-12-13 US claimed
US-5245035-A HETEROCYCLIC BORON COMPOUNDS AS INTERMEDIATES FOR ANGIOTENSIN II ANTAGONISTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-09-14 US claimed
EP-0539066-A1 Heterocyclic compounds useful as angiotensin II antagonists ZENECA LIMITED (GB) 1993-04-28 EP claimed
EP-0495626-A1 Process for the preparation of tetrazole derivatives ZENECA LIMITED (GB) 1992-07-22 EP claimed
EP-0495627-A1 Boron compounds ZENECA LIMITED (GB) 1992-07-22 EP claimed
EP-0124752-B1 MIXTURES OF SUBSTANCES WITH GROWTH AND OUTPUT ACCELERATING EFFECT AS WELL AS FEED AND WATERING LIQUIDS WHICH CONTAIN LOW AMOUNTS OF THESE MIXTURES BASF Aktiengesellschaft (DE) 1986-07-16 EP claimed
US-4496727-A ORGANIC PIGMENTS; PLASTICS; LACQUERS; INKS; COATINGS; COLOR FASTNESS CIBA-GEIGY CORPORATION (US) 1985-01-29 US claimed
EP-0065192-B1 GROWTH-PROMOTING FODDER OR DRINKING LIQUID BASF Aktiengesellschaft (DE) 1984-02-01 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240269308-A1 PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF TOP1, TOP2A, QPCT CYP1A2 1881/4885NCF1 2276/4885L3MBTL1 2490/4885
US-20220015363-A1 SMALL MOLECULE PATHOGEN DISPERSAL AGENT RECQL, POLQ, HIRA CYP1A2 2983/4885NCF1 2308/4885L3MBTL1 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.